* hepatitis A (HAV)
** type of virus
RNA
** transmission
fecal-oral
* hepatitis B (HBV)
** type of virus
DNA
** transmission
bloodborne
** vaccination
*** monovalent
- Energix-B
- Recombivax HB
- Heplisav-B
*** bivalent
Twinrix
** treatments :l:
*** Pegylated Inteferon Alfa (PegIFN)
**** brand
Pegasys
*** Nucleo[st]ide Reverse Transcriptase Inhibitors (NRTIs)
**** agents :l:
***** Tenofovir disoproxil fumarate (TDF)
****** brand
Viread®
****** black box warning
severe acute HBV exacerbations upon discontinuation
***** Tenofovir alafenamide fumarate (TAF)
****** brand
Vemlidy®
****** black box warning
severe acute HBV exacerbations upon discontinuation
***** Entecavir (ETV)
****** brand
Baraclude®
***** Lamivudine
****** brand
Epivir HBV®
***** Adefovir
****** brand
Hepsera®
** choosing therapy
*** patient-specific factors that need to be considered
1. Family planning
2. Medication cost
3. Previous history of lamivudine resistance
4. Anticipated tolerability of treatment side effects
5. Comorbidities
*** [#A] no comorbidities
- ETV
- TAF
- TDF
*** comorbidities
**** [#A] bone or renal disease
Choose {ETV, TAF} over TDF
***** TAF > ETV
- HIV coinfection
- previous nucleoside exposure
- CrCl ≥ 15; thus needing no dose adjustment
***** ETV > TAF
- CrCl < 15
- cost
* hepatitis C (HCV)
** unique properties
- reinfection possible
- no vaccine
** type of virus
RNA
** transmission
bloodborne
** [#A] types of people to screen
- baby boomers
- IV drug users
- prisoners
- healthcare workers
- HIV infected persons
** chronic infection treatment
direct-acting antivirals
** testing sequence for identifying current HCV infection
*** HCV antibody test
**** positive; reactive
***** detected HCV RNA
current HCV infection, so apply care
***** not detected HCV RNA
additional testing as appropriate
**** negative; non-reactive
nonreactive ⇒ no HCV antibody detected
** treatment
*** drug acting antivirals (DAA)
**** NS3/4A Protease Inhibitor :l:
***** Simeprevir (SMV)
****** brand
Olysio
***** Paritaprevir (PTR)
***** Grazoprevir (GZR)
***** Glecaprevir (GLE)
***** Voxilaprevir (VOX)
**** NS5A Inhibitor :l:
***** Ledipasvir (LDV)
***** Ombitasvir (OBV)
***** Daclatasvir (DCV)
****** brand
Daklinza®
***** Elbasvir (EBR)
***** Velpatasvir (VEL)
***** Pibrentasvir (PIB)
**** NS5B Polymerase Inhibitor :l:
***** Sofosbuvir (SOF)
****** brand
Sovaldi
****** adverse drug reactions
serious symptomatic bradycardia when coadministered with amiodarone
***** Dasabuvir (DSV)
**** combinations :l:
***** Harvoni®
- Ledipasvir (LDV)
- Sofosbuvir (SOF)
***** Viekira Pak®
- OBV-PTR-ritonavir
- DSV
***** Zepatier®
- elbasavir
- grazoprevir
***** Epclusa®
- sofosbuvir
- velpatasvir
***** Mavyret®
- glecaprevir
- pibrentasvir
***** Vosevi® :l:
- sofosbuvir
- velpatasvir
- voxilaprevir
